- MammaTyper® is superior to local immunohistochemistry (IHC) for measuring local gene expression in order to predict Oncotype DX®-type results(1)
- Use of MammaTyper® subtyping for prognosis of breast cancer suggests that endocrine therapy may be adequate for patients with a low risk of relapse(2)
- This study demonstrated that MammaTyper® is a cost-effective method to identify low-risk patients.
Mainz, Germany, January 15, 2018 / B3C newswire / -- BioNTech Diagnostics GmbH is announcing new results from two studies on the MammaTyper® test which were presented at the Breast Cancer Symposium in San Antonio in December.(1,2) The results of these studies again demonstrate the benefits of breast cancer subtyping using MammaTyper® to predict the course of the disease and to aid in the selection of effective, tailored therapy. MammaTyper® allows precise, quantitative measurement of the mRNA expression of the ERBB2 (HER2), ESR1 (ER), PGR (PR) and MKI67 (proliferation marker Ki-67) biomarkers, which in turn facilitates molecular subtyping of tumor tissue according to St. Gallen guidelines. MammaTyper® thus provides accurate molecular stratification of breast cancer, information which is required for the selection of effective therapy tailored to each patient.(3) "Quantitative measurement of the expression levels of the four St. Gallen biomarkers was a much better predictor of Oncotype DX® Recurrence Score (RS) results than using traditional IHC methods" according to Dr. Mark Laible, Head of Molecular Pathology at BioNTech Diagnostics. "An additional study could show that the MammaTyper® test also helps physicians avoid overtreating certain patient groups, thus sparing patients from additional rounds of debilitating chemotherapy" added Dr. Sierk Pötting, CFO BioNTech Diagnostics GmbH.
The study results in detail:
Study on the ability of MammaTyper® to predict Oncotype DX®-type results by measuring local gene expression(1)
This retrospective study conducted in Germany and Switzerland was a collaboration between the Institute of Pathology at the Bodensee Medical Campus in Friedrichshafen, the OptiPath Pathology Health Center in Frankfurt am Main, and BioNTech Diagnostics GmbH in Mainz in Germany, and the Institute for Surgical Pathology at the University Hospital of Zürich, Switzerland. The study analyzed the power of standardized measurement of the expression levels of HER2, ER, PR, and Ki67 using MammaTyper® to predict a low risk of distant metastasis on the Oncotype Recurrence Score compared with immunohistochemical detection of these biomarkers. A total of 198 FFPE breast cancer tissue samples were analyzed retrospectively using MammaTyper®, of which 38% (n=76) were typed as luminal A-like. The Recurrence Score (RS) was <25 for 99% of samples, and <18 for 70%. MammaTyper® thus allows the identification of patients with a low risk for distant metastasis, who do not benefit from adjuvant chemotherapy versus endocrine therapy alone (RS<25). The study could clearly demonstrate that analyzing mRNA expression using MammaTyper® was superior to IHC-based methods at predicting RS. It is not possible to fully standardize measurement of the proliferation marker Ki67 using semi-quantitative ICH. In contrast, due to its high degree of standardization, local measurement of gene expression may represent a more reliable method to identify patients with a low risk of relapse according to Oncotype DX® criteria.
Study on the ability of MammaTyper® to predict distant metastasis in low-risk breast cancer patients using RT-qPCR-based subtyping(2)
This retrospective analysis investigated the predictive power of molecular subtyping of archived samples from low-risk breast cancer patients using MammaTyper®. It was conducted by BioNTech Diagnostics and the PATH Biobank with its network of six breast cancer centers in Germany. The tissue samples were collected between 2005 and 2011 from patients who had received only adjuvant endocrine therapy. The inclusion criteria were (1) FFPE samples from female invasive breast cancer which (2) had been typed as ER-positive and HER-negative by IHC/ISH at the initial diagnosis. Patients could not have (3) distant metastases at the time of diagnosis, and (4) could not have received any treatment other than endocrine therapy.
Distant metastases were later identified in 8.5% of the 319 patients providing samples after a mean follow-up of 7.8 years. MammaTyper® identified 60% (n=192) of the samples as luminal A-like; 4.7% (n=9) of these later exhibited distant metastases. According to the test, 37% (n=119) of the samples were of the luminal B-like subtype (HER2-negative), of which 13.4% (n=16) later exhibited distant metastases. 1.3% (n=4) of samples were classified as triple negative (ductal), 25% (n=1) of which later exhibited distant metastases. 0.6% (n=2) samples were classified as not conforming to St. Gallen criteria, of which 50% (n=1) later exhibited distant metastases. There were no distant metastases for luminal B-like (HER2-positive) samples (0.6%, n=2). In contrast, patients with samples classified as luminal A-like experienced significantly longer disease-free survival regardless of the number of involved lymph nodes.
Measurement of the mRNA levels of HER2, ER, PR, and Ki67 facilitates molecular subtyping according to the St. Gallen classification. A low risk of distant metastasis could be confirmed for samples classified by MammaTyper as luminal A-like. The high degree of standardization for mRNA measurement by MammaTyper may promote the use of the proliferation biomarker Ki67/MKI67 in the routine pathology of breast cancer.
MammaTyper® is a molecular in vitro diagnostic test for quantitative detection of the mRNA expression status of the genes ERBB2 (HER2), ESR1 (ER), PGR (PR) and of MKI67 (proliferation marker Ki-67) in the tumour tissue of female patients with newly diagnosed invasive breast cancer. The test has been validated for total RNA extracted from tissue specimens or biopsies.
MammaTyper® is used for molecular subtyping of breast cancer tissue according to the St Gallen classification (2013) in luminal A-like, luminal B-like (HER2 negative), luminal B-like (HER2 positive), HER2 positive (non-luminal) and triple negative (ductal) tumours, and offers together with further clinical pathological factors the possibility of significantly improving the diagnostic and the treatment of female patients with breast cancer. The test can be carried out in any pathology laboratory. MammaTyper® can be used on all female patients with newly diagnosed invasive breast cancer and provides the results on the same day. With MammaTyper®, BioNTech underlines its commitment to making personalized medicine generally available in the field of cancer treatment.
About BioNTech Group
BioNTech Group, consisting of BioNTech AG and its subsidiaries, is an immunotherapy leader with bench-to-market capabilities, developing truly personalized, well-tolerated and potent treatments for cancer and other diseases. Established by clinicians and scientists the Group is pioneering disruptive technologies ranging from individualized mRNA based medicines through innovative Chimeric Antigen Receptors /T-cell Receptor-based products and novel antibody checkpoint immunomodulators. BioNTech’s clinical programs are supported by an in-house molecular diagnostics unit whose products include MammaTyper® a molecular in-vitro diagnostic kit, marketed as IVD under CE marking in the European Union (and Switzerland) and in certain other countries. Founded in 2008, BioNTech is privately held, with Strüngmann Family Office as a majority shareholder, having closed the largest initial financing in the European biopharma sector’s history.
About BioNTech Diagnostics GmbH
BioNTech Diagnostics is a fully-owned subsidiary company of BioNTech AG. The ISO 9001/13485 certified company has extensive product and service offerings ranging from biomarker discovery and validation through molecular screening assays, patient stratification and companion diagnostics to clinical monitoring, all to international regulatory standards. Early detection of diseases that have a high mortality rate and the appropriate selection of therapies are crucial for a successful treatment of patients. BioNTech Diagnostics’ mission is to provide new and innovative diagnostic tests to extend lives of patients, improve their quality of life and support the use of appropriate therapy for each individual patient.
BioNTech Diagnostics GmbH
Dr. Gerd Hempel
COMMPartners GmbH Co. KG
- Lehr et al.; Prediction of Oncotype DX® results based on local gene expression measurements by MammaTyper®. San Antonio Breast Cancer Symposium – December 5–9, 2017 | P1-06-11.
- Laible et al.; Prediction of distant recurrence in low risk early breast cancer by RT-qPCR based subtyping using MammaTyper®. San Antonio Breast Cancer Symposium – December 5–9, 2017 | P3-08-14.
- Wirtz Ralph M et al. (2016) Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. Breast Cancer Res Treat. DOI 10.007/s10549-016-3835-7 (Published online 24 May 2016).